PMV Pharmaceuticals Statistics
Total Valuation
PMVP has a market cap or net worth of $57.13 million. The enterprise value is -$124.46 million.
Important Dates
The last earnings date was Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PMVP has 51.93 million shares outstanding. The number of shares has increased by 7.42% in one year.
| Current Share Class | 51.93M |
| Shares Outstanding | 51.93M |
| Shares Change (YoY) | +7.42% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 2.41% |
| Owned by Institutions (%) | 45.19% |
| Float | 34.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.22 |
| Quick Ratio | 11.79 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.23% and return on invested capital (ROIC) is -25.48%.
| Return on Equity (ROE) | -29.23% |
| Return on Assets (ROA) | -23.92% |
| Return on Invested Capital (ROIC) | -25.48% |
| Return on Capital Employed (ROCE) | -47.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.25M |
| Employee Count | 47 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -16.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.65% in the last 52 weeks. The beta is 1.45, so PMVP's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -37.65% |
| 50-Day Moving Average | 1.34 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 23.13 |
| Average Volume (20 Days) | 99,859 |
Short Selling Information
The latest short interest is 886,286, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 886,286 |
| Short Previous Month | 876,945 |
| Short % of Shares Out | 1.71% |
| Short % of Float | 2.56% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -84.85M |
| Pretax Income | -65.05M |
| Net Income | -58.71M |
| EBITDA | -83.71M |
| EBIT | -84.85M |
| Earnings Per Share (EPS) | -$1.14 |
Full Income StatementBalance Sheet
The company has $169.45 million in cash and $1.19 million in debt, giving a net cash position of $182.11 million or $3.51 per share.
| Cash & Cash Equivalents | 169.45M |
| Total Debt | 1.19M |
| Net Cash | 182.11M |
| Net Cash Per Share | $3.51 |
| Equity (Book Value) | 176.08M |
| Book Value Per Share | 3.39 |
| Working Capital | 161.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$51.28 million and capital expenditures -$655,000, giving a free cash flow of -$51.94 million.
| Operating Cash Flow | -51.28M |
| Capital Expenditures | -655,000 |
| Free Cash Flow | -51.94M |
| FCF Per Share | -$1.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |